Company Profile
Innovent Biologics, Inc., a biopharmaceutical company provides the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and globally.
The company discovers, develops, manufactures, and commercializes monoclonal antibodies and drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.
Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection).
Additionally, it sells and distributes pharmaceutical products; and offers consultation and R&D services. Incorporated in 2011, the company is headquartered in Suzhou, the People's Republic of China.